Supplement

Molecular markers, minimal residual disease, gene expression profiling, microRNAs, chronic myelogenous leukemia, non-Hodg-kin’s lymphoma, acute leukemias, targeted therapies, tyrosine ki-nase inhibitors, imatinib, rituximab, PCR, RT-PCR, BCR-ABL, kinase domain mutations, CML stem cells The introduction of targeted therapies has revolutionized treat-ment and improved outcomes in patients with leukemias and lym-phomas. However, many patients experience relapse caused by the persistence of residual malignant cells. Cytogenetic and molecular techniques are increasingly being used to assess and quantify mini-mal residual disease (MRD). The emergence of advanced technolo-gies has led to the discovery of multiple novel molecular markers that can be used to detect MRD and predict outcome in patients with leukemias and lymphomas. Gene expression signatures tha